207 related articles for article (PubMed ID: 9659170)
1. Evidence for altered hepatic matrix degradation in genetic haemochromatosis.
George DK; Ramm GA; Powell LW; Fletcher LM; Walker NI; Cowley LL; Crawford DH
Gut; 1998 May; 42(5):715-20. PubMed ID: 9659170
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum type IV collagen: a sensitive indicator of the presence of cirrhosis in haemochromatosis.
George DK; Ramm GA; Walker NI; Powell LW; Crawford DH
J Hepatol; 1999 Jul; 31(1):47-52. PubMed ID: 10424282
[TBL] [Abstract][Full Text] [Related]
3. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response.
Kasahara A; Hayashi N; Mochizuki K; Oshita M; Katayama K; Kato M; Masuzawa M; Yoshihara H; Naito M; Miyamoto T; Inoue A; Asai A; Hijioka T; Fusamoto H; Kamada T
J Hepatol; 1997 Mar; 26(3):574-83. PubMed ID: 9075665
[TBL] [Abstract][Full Text] [Related]
4. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid.
Leroy V; Monier F; Bottari S; Trocme C; Sturm N; Hilleret MN; Morel F; Zarski JP
Am J Gastroenterol; 2004 Feb; 99(2):271-9. PubMed ID: 15046217
[TBL] [Abstract][Full Text] [Related]
5. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases -1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis.
Walsh KM; Timms P; Campbell S; MacSween RN; Morris AJ
Dig Dis Sci; 1999 Mar; 44(3):624-30. PubMed ID: 10080160
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic potential of serum matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as non-invasive markers of hepatic fibrosis in patients with HCV related chronic liver disease.
El-Gindy I; El Rahman AT; El-Alim MA; Zaki SS
Egypt J Immunol; 2003; 10(1):27-35. PubMed ID: 15719620
[TBL] [Abstract][Full Text] [Related]
7. Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis.
Kossakowska AE; Edwards DR; Lee SS; Urbanski LS; Stabbler AL; Zhang CL; Phillips BW; Zhang Y; Urbanski SJ
Am J Pathol; 1998 Dec; 153(6):1895-902. PubMed ID: 9846979
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of platelet derived growth factor-BB, transforming growth factor-beta1, matrix metalloproteinase-1, and tissue inhibitor of matrix metalloproteinase-1 in serum and peripheral blood mononuclear cells for hepatic fibrosis.
Zhang BB; Cai WM; Weng HL; Hu ZR; Lu J; Zheng M; Liu RH
World J Gastroenterol; 2003 Nov; 9(11):2490-6. PubMed ID: 14606082
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease.
Navratilova Z; Zatloukal J; Kriegova E; Kolek V; Petrek M
Respirology; 2012 Aug; 17(6):1006-12. PubMed ID: 22591289
[TBL] [Abstract][Full Text] [Related]
10. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
[TBL] [Abstract][Full Text] [Related]
11. Serum biomarkers of fibrosis and extracellular matrix remodeling in patients with nonalcoholic fatty liver disease: association with liver histology.
Yilmaz Y; Eren F
Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):43-46. PubMed ID: 30134384
[TBL] [Abstract][Full Text] [Related]
12. The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity.
Toubi E; Kessel A; Grushko G; Sabo E; Rozenbaum M; Rosner I
Clin Exp Rheumatol; 2002; 20(2):221-4. PubMed ID: 12051403
[TBL] [Abstract][Full Text] [Related]
13. Abnormalities of the extracellular degradation of collagen type I in essential hypertension.
Laviades C; Varo N; Fernández J; Mayor G; Gil MJ; Monreal I; Díez J
Circulation; 1998 Aug; 98(6):535-40. PubMed ID: 9714110
[TBL] [Abstract][Full Text] [Related]
14. Significance of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in chronic hepatitis C patients.
Badra G; Lotfy M; El-Refaie A; Obada M; Abdelmonem E; Kandeel S; Fathy A
Acta Microbiol Immunol Hung; 2010 Mar; 57(1):29-42. PubMed ID: 20350877
[TBL] [Abstract][Full Text] [Related]
15. Serum matrix metalloproteinase-9:Tissue inhibitor of metalloproteinase-1 ratio correlates with steroid responsiveness in moderate to severe asthma.
Bossé M; Chakir J; Rouabhia M; Boulet LP; Audette M; Laviolette M
Am J Respir Crit Care Med; 1999 Feb; 159(2):596-602. PubMed ID: 9927378
[TBL] [Abstract][Full Text] [Related]
16. Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1?
Marín F; Roldán V; Climent V; Garcia A; Marco P; Lip GY
Stroke; 2003 May; 34(5):1181-6. PubMed ID: 12663879
[TBL] [Abstract][Full Text] [Related]
17. Levels of circulating collagenase, stromelysin-1, and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis. Relationship to serum levels of antigenic keratan sulfate and systemic parameters of inflammation.
Manicourt DH; Fujimoto N; Obata K; Thonar EJ
Arthritis Rheum; 1995 Aug; 38(8):1031-9. PubMed ID: 7639798
[TBL] [Abstract][Full Text] [Related]
18. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients.
Iizasa T; Fujisawa T; Suzuki M; Motohashi S; Yasufuku K; Yasukawa T; Baba M; Shiba M
Clin Cancer Res; 1999 Jan; 5(1):149-53. PubMed ID: 9918213
[TBL] [Abstract][Full Text] [Related]
19. Serum matrix metalloproteinase-1 in patients with chronic viral hepatitis.
Murawaki Y; Ikuta Y; Idobe Y; Kawasaki H
J Gastroenterol Hepatol; 1999 Feb; 14(2):138-45. PubMed ID: 10029294
[TBL] [Abstract][Full Text] [Related]
20. Occurrence of matrix metalloproteinases and tissue inhibitors of metalloproteinases in tuberculous pleuritis.
Hoheisel G; Sack U; Hui DS; Huse K; Chan KS; Chan KK; Hartwig K; Schuster E; Scholz GH; Schauer J
Tuberculosis (Edinb); 2001; 81(3):203-9. PubMed ID: 11466032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
